TNF-alpha levels in tears: A novel biomarker to assess the degree of diabetic retinopathy

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Costagliola, C ^a   Romano, V ^b   De Tollis, M ^c   Aceto, F ^a   Dell'Omo, R ^a   Romano, M R ^a   Pedicino, C ^c   Semeraro, F ^d  

^a UNIVERSITY OF MOLISE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Casa di Cura Villa Maria   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; TUMOR NECROSIS FACTOR ALPHA; ALBUMINOID; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LACRIMAL FLUID; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; CHEMISTRY; DIABETIC NEPHROPATHY; METABOLISM; MIDDLE AGED;

AGED; ALBUMINS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887367824     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/629529     Document Type: Article

References (52)

1. Nunan D., Mahtani K. R., Roberts N., Heneghan C., Physical activity for the prevention and treatment of major chronic disease: an overview of systematic reviews. Systematic Reviews 2013 2 56 10.1186/2046-4053-2-56
2. Madden K. M., Evidence for the benefit of exercise therapy in patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 2013 6 233 239
3. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 6865 813 820 2-s2.0-0035856980 10.1038/414813a (Pubitemid 34000785)
4. King H., Aubert R. E., Herman W. H., Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 21 9 1414 1431 2-s2.0-0031752685 (Pubitemid 28405191)
5. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early treatment diabetic retinopathy study Research Group. Ophthalmology 1991 98 supplement 5 807 822
6. Henricsson M., Tyrberg M., Heijl A., Janzon L., Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmologica Scandinavica 1996 74 6 533 538 2-s2.0-0030453824 (Pubitemid 27042672)
7. Henricsson M., Nilsson A., Groop L., Heijl A., Janzon L., Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmologica Scandinavica 1996 74 6 523 527 2-s2.0-0030482581 (Pubitemid 27042670)
8. Hove M. N., Kristensen J. K., Lauritzen T., Bek T., The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmologica Scandinavica 2004 82 4 443 448 2-s2.0-4444366881 10.1111/j.1600-0420.2004.00270.x (Pubitemid 39199446)
9. Curtis T. M., Gardiner T. A., Stitt A. W., Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye 2009 23 7 1496 1508 2-s2.0-67749088340 10.1038/eye.2009.108
10. Zong H., Ward M., Madden A., Yong P. H., Limb G. A., Curtis T. M., Stitt A. W., Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010 53 12 2656 2666 2-s2.0-78649333713 10.1007/s00125-010-1900-z
11. Goldberg R. B., Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. Journal of Clinical Endocrinology and Metabolism 2009 94 9 3171 3182 2-s2.0-69949093803 10.1210/jc.2008-2534
12. Cheung N., Mitchell P., Wong T. Y., Diabetic retinopathy. The Lancet 2010 376 9735 124 136 2-s2.0-77955013602 10.1016/S0140-6736(09)62124-3
13. Nguyen T. T., Alibrahim E., Islam F. M. A., Klein R., Klein B. E. K., Cotch M. F., Shea S., Wong T. Y., Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care 2009 32 9 1704 1709 2-s2.0-69549112950 10.2337/dc09-0102
14. Klein B. E. K., Knudtson M. D., Tsai M. Y., Klein R., The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: wisconsin epidemiologic study of diabetic retinopathy. Archives of Ophthalmology 2009 127 9 1175 1182 2-s2.0-70349243143 10.1001/archophthalmol.2009.172
15. Hotamisligil G. S., Budavari A., Murray D., Spiegelman B. M., Reduced tyrosine kinase activity of the insulin receptor in obesity- diabetes. Central role of tumor necrosis factor Journal of Clinical Investigation 1994 94 4 1543 1549 2-s2.0-0028031569
16. Joussen A. M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., Adamis A. P., Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. The FASEB Journal 2002 16 3 438 440 2-s2.0-0036517850
17. Zhang S. X., Wang J. J., Gao G., Shao C., Mott R., Ma J.-X., Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. The FASEB Journal 2006 20 2 323 325 2-s2.0-33644893607 10.1096/fj.05-4313fje (Pubitemid 46671158)
18. Moller D. E., Potential role of TNF in the pathogenesis of insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 2000 11 6 212 217 2-s2.0-0033867178 10.1016/S1043-2760(00)00272-1 (Pubitemid 30603166)
19. Franks W. A., Limb G. A., Stanford M. R., Ogilvie J., Wolstencroft R. A., Chignell A. H., Dumonde D. C., Cytokines in human intraocular inflammation. Current Eye Research 1992 11 187 191 2-s2.0-0026671219
20. Limb G. A., Chignell A. H., Green W., LeRoy F., Dumonde D. C., Distribution of TNF and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. British Journal of Ophthalmology 1996 80 2 168 173 2-s2.0-0030065211 (Pubitemid 26058553)
21. Spranger J., Meyer-Schwickerath R., Klein M., Schatz H., Pfeiffer A., TNF-alpha level in vitreous. Increase in neovascular eye disease and proliferative diabetic retinopathy. Medizinische Klinik 1995 90 3 134 137 2-s2.0-0029257075
22. Lechleitner M., Koch T., Herold M., Dzien A., Hoppichler F., Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. Journal of Internal Medicine 2000 248 1 67 76 2-s2.0-0033941219 10.1046/j.1365-2796. 2000.00705.x (Pubitemid 30470006)
23. Yuuki T., Kanda T., Kimura Y., Kotajima N., Tamura J., Kobayashi I., Kishi S., Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. Journal of Diabetes and Its Complications 2001 15 5 257 259 2-s2.0-0034876205 10.1016/S1056-8727(01)00155-6 (Pubitemid 32750613)
24. Limb G. A., Webster L., Soomro H., Janikoun S., Shilling J., Platelet expression of tumour necrosis factor-alpha (TNF), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clinical and Experimental Immunology 1999 118 2 213 218 2-s2.0-0032707318 10.1046/j.1365-2249.1999.01067.x (Pubitemid 29519250)
25. 1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina. Journal of Diabetes Research 2013 2013 9 658548 10.1155/2013/658548
26. Hotamisligil G. S., Inflammation and metabolic disorders. Nature 2006 444 7121 860 867 2-s2.0-33845866857 10.1038/nature05485 (Pubitemid 46024993)
27. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
28. Vinores S. A., Xiao W.-H., Shen J., Campochiaro P. A., TNF- is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. Journal of Neuroimmunology 2007 182 1-2 73 79 2-s2.0-33846016638 10.1016/j.jneuroim.2006.09.015 (Pubitemid 46039759)
29. Joussen A. M., Doehmen S., Le M. L., Koizumi K., Radetzky S., Krohne T. U., Poulaki V., Semkova I., Kociok N., TNF- mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Molecular Vision 2009 15 1418 1428 2-s2.0-68149131912
30. Limb G. A., Hollifield R. D., Webster L., Charteris D. G., Chignell A. H., Soluble TNF receptors in vitreoretinal proliferative disease. Investigative Ophthalmology and Visual Science 2001 42 7 1586 1591 2-s2.0-0035013685 (Pubitemid 32520752)
31. Limb G. A., Soomro H., Janikoun S., Hollifield R. D., Shilling J., Evidence for control of tumour necrosis factor-alpha (TNF-) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clinical and Experimental Immunology 1999 115 3 409 414 2-s2.0-0033030513 10.1046/j.1365-2249.1999.00839.x (Pubitemid 29130353)
32. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012 35 supplement 1 S64 S71
33. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Early treatment diabetic retinopathy study research group. Ophthalmology 1991 98 supplement 5 786 806
34. Cockcroft D. W., Gault M. H., Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 1 31 41 2-s2.0-0016916438
35. Khyshituev B. S., Maksimenia M. V., Kozlov S. A., Diagnostic value of tear tests in diabetic retinopathy (a literature review). Klinicheskaia Laboratornaia Diagnostika 2006 3 34 36 2-s2.0-33746051363
36. Liu J., Shi B., He S., Yao X., Willcox M. D. P., Zhao Z., Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Molecular Vision 2010 16 2931 2938 2-s2.0-79551712372
37. Behl Y., Krothapalli P., Desta T., DiPiazza A., Roy S., Graves D. T., Diabetes-enhanced tumor necrosis factor- production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. The American Journal of Pathology 2008 172 5 1411 1418 2-s2.0-43449109783 10.2353/ajpath.2008.071070 (Pubitemid 351671553)
38. Kuo J. Z., Guo X., Klein R., Klein B. E., Cui J., Rotter J. I., Ipp E., Chen Y.-D. I., Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. Ophthalmology 2012 119 5 1041 1046 2-s2.0-84860427351 10.1016/j.ophtha.2011.10.040
39. Roy M. S., Janal M. N., Crosby J., Donnelly R., Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes. Investigative Ophthalmology & Visual Science 2013 54 8 5471 5480 10.1167/iovs.13-12212
40. Muni R. H., Kohly R. P., Lee Q., Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmology 2013 131 4 514 521 10.1001/ jamaophthalmol.2013.2299
41. Sartippour M. R., Renier G., Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Diabetes 2000 49 4 597 602 2-s2.0-0034072181 (Pubitemid 30183748)
42. Costa G. N., Vindeirinho J., Cavadas C., Ambrósio A. F., Santos P. F., Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose. Molecular and Cellular Neuroscience 2012 50 1 113 123 2-s2.0-84860624256 10.1016/j.mcn.2012.04.003
43. Colagiuri S., Davies D., The value of early detection of type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 2 95 99 2-s2.0-66149149526 10.1097/MED.0b013e328329302f
44. Organization W. H., Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2006
45. Ealovega M. W., Tabaei B. P., Brandle M., Burke R., Herman W. H., Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 2004 27 1 9 12 2-s2.0-1042268732 10.2337/diacare.27.1.9 (Pubitemid 38196701)
46. Newman D. J., Mattock M. B., Dawnay A. B., Kerry S., McGuire A., Yaqoob M., Hitman G. A., Hawke C., Systematic review on urine albumin testing for early detection of diabetic complications. Health Technology Assessment 2005 9 30 9 12 2-s2.0-33644804274
47. Olafsdottir E., Andersson D. K., Dedorsson I., Stefánsson E., The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmol 2013 10.1111/aos.12095
48. Zhang X., Saaddine J. B., Chou C.-F., Cotch M. F., Cheng Y. J., Geiss L. S., Gregg E. W., Albright A. L., Klein B. E. K., Klein R., Prevalence of diabetic retinopathy in the United States, 2005-2008. Journal of the American Medical Association 2010 304 6 649 656 2-s2.0-77955376918 10.1001/jama.2010.1111
49. Meleth A. D., Agrón E., Chan C.-C., Serum inflammatory markers in diabetic retinopathy. Investigative Ophthalmology & Visual Science 2005 46 11 4295 4301 10.1167/iovs.04-1057 (Pubitemid 44264635)
50. Barton K., Monroy D. C., Nava A., Pflugfelder S. C., Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997 104 11 1868 1874 2-s2.0-0031406702 (Pubitemid 28100344)
51. Oshida T., Iwata M., Sakimoto T., Sawa M., Tumor necrosis factor-alpha in tears of patients with Sjögren syndrome. Nippon Ganka Gakkai Zasshi 2004 108 5 297 301 2-s2.0-3042781378
52. Yoon K.-C., Jeong I.-Y., Park Y.-G., Yang S.-Y., Interleukin-6 and tumor necrosis factor- levels in tears of patients with dry eye syndrome. Cornea 2007 26 4 431 437 2-s2.0-34247607163 10.1097/ICO.0b013e31803dcda2 (Pubitemid 46684384)